Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 12 clinical trials
Safety Tolerability Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer

ASK120067 Tablets is a Epidermal Growth Factor Receptor (EGFR) mutation selective Tyrosine Kinase Inhibitor which can efficient suppress the EGFR T790M drug-resistant mutation tumor cell in

  • 32 views
  • 25 Jan, 2021
  • 3 locations
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).

solid tumour
lung carcinoma
EGFR
epidermal growth factor receptor
growth factor
  • 27 views
  • 25 Jul, 2021
  • 326 locations
SBRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs

This study is an open-label, single-arm phase 2 trial to evaluate the efficacy and safety of stereotactic body radiotherapy (SBRT) for patients with residual oligometastases of NSCLC after 3rd generation EGFR-TKIs.

  • 0 views
  • 04 Mar, 2021
  • 1 location
Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)

" for EGFR T790M status due to non-informative or unfeasible tumor rebiopsy, and a negative finding for EGFR T790M in a standard plasma genotyping assay. All patients will receive osimertinib as

EGFR
lung carcinoma
gefitinib
erlotinib
afatinib
  • 1 views
  • 24 Jan, 2021
  • 1 location
Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

This phase Ib trial studies the best dose, safety, and effect of alisertib or sapanisertib, in combination with osimertinib, in treating patients with EGFR mutated stage IIIB or IV non-small cell lung cancer that does not respond to osimertinib treatment (osimertinib resistant). Osimertinib, alisertib, and sapanisertib may stop the growth …

neutrophil count
pd-l1
hemoglobin a1c
measurable disease
periodic abstinence
  • 0 views
  • 11 Apr, 2021
Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

This phase Ib trial studies the side effects and best dose of telaglenastat hydrochloride when given together with osimertinib in treating patients with stage IV non-small cell lung cancer and a mutation in the EGFR gene. Telaglenastat hydrochloride and osimertinib may stop the growth of tumor cells by blocking some …

telaglenastat
neutrophil count
hcv viral load
measurable disease
cb-839 hcl
  • 10 views
  • 12 Jun, 2021
  • 5 locations
Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC

craniocerebral radiotherapy significantly prolonged OS. The first-line treatment of the third generation of EGFR-TKI targeting drug Almonertinib for EGFR-positive NSCLC can eliminate the possible EGFR

EGFR
lung carcinoma
neutrophil count
brain metastases
cancer chemotherapy
  • 0 views
  • 12 Jun, 2021
  • 1 location
Study Targeting EGFR Resistance Mechanisms in NSCLC

This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-945, a selective EGFR inhibitor.

  • 0 views
  • 06 May, 2021
  • 1 location
Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

The best drug sequencing of dacomitinib or osimertinib in patients with advanced or metastatic Epidermal Growth Factor Receptor (EGFR) mutation positive non-small-cell lung cancer (NSCLC) has not yet been determined. The study enables investigation of the efficacy of dacomitinib followed by or subsequent to osimertinib osimertinib in patients with classical …

  • 0 views
  • 13 May, 2021
  • 20 locations
LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer

The goal of this project is to characterize the genetic profile of patients with advanced stage IIIB/IV non-small cell lung cancer (NSCLC) using liquid biopsies

EGFR
lung carcinoma
HER2
epidermal growth factor receptor
growth factor
  • 19 views
  • 23 Jan, 2021
  • 12 locations